Four children in three unrelated families (one consanguineous) presented with lethargy, hyperlactatemia, and hyperammonemia of unexplained origin during the neonatal period and early childhood. We identified and validated three different CA5A alterations, including a homozygous missense mutation (c.697T>C) in two siblings, a homozygous splice site mutation (c.555G>A) leading to skipping of exon 4, and a homozygous 4 kb deletion of exon 6. The deleterious nature of the homozygous mutation c.697T>C (p.Ser233Pro) was demonstrated by reduced enzymatic activity and increased temperature sensitivity. Carbonic anhydrase VA (CA-VA) was absent in liver in the child with the homozygous exon 6 deletion. The metabolite profiles in the affected individuals fit CA-VA deficiency, showing evidence of impaired provision of bicarbonate to the four enzymes that participate in key pathways in intermediary metabolism: carbamoylphosphate synthetase 1 (urea cycle), pyruvate carboxylase (anaplerosis, gluconeogenesis), propionyl-CoA carboxylase, and 3-methylcrotonyl-CoA carboxylase (branched chain amino acids catabolism). In the three children who were administered carglumic acid, hyperammonemia resolved. CA-VA deficiency should therefore be added to urea cycle defects, organic acidurias, and pyruvate carboxylase deficiency as a treatable condition in the differential diagnosis of hyperammonemia in the neonate and young child.
Hyperammonemia is a medical emergency that requires immediate and targeted treatment. Correct diagnosis is therefore essential, but it is challenging given heterogeneous etiologies, including genetic (inborn errors of metabolism), developmental (transient neonatal hyperammonemia), and environmental (infectious hepatitis, medication) causes. 1 We present four children from three unrelated families with infantile hyperammonemic encephalopathy and hyperlactatemia. The underlying cause in each of these children was deficiency of carbonic anhydrase VA (CA-VA) (CA5A [MIM 114671]), an inborn error of metabolism broadening the differential diagnosis for hyperammonemia. This study was initiated as part of the Treatable Intellectual Disability Endeavor in British Columbia and approved by the institutional review boards of BC Children's Hospital and the University of British Columbia. Parents provided written informed consent.
In family 1, the female index (II-1 in Figure 1 ), her younger affected brother (II-2), and her unaffected sister (II-3) were born to healthy nonconsanguineous parents of Belgian-Scottish descent after uneventful pregnancies and deliveries. The index and her male sibling developed lethargy, tachypnea, hypoglycemia (2.2 and 2.9 mmol/l), hyperlactatemia (9.8 and 8.8 mmol/l), hypernatremia (Na 152 and 150 mmol/l), and hyperammonemia (780 and 238 mmol/l) with respiratory alkalosis (pH 7.48, pCO 2 Clinical and metabolic findings normalized in both siblings with the administration of intravenous dextrose and bicarbonate, as well as enteral carglumic acid (Carbaglu). In our institution, carglumic acid is used to resolve hyperammonemia of unknown origin. 2 Brain MRI and MRS on day 5 of life revealed a small periventricular petechial focus near the trigone of the right lateral ventricle, with a small lactate peak on spectroscopy in the male sibling; in the female sibling, both MRI and EEG were unremarkable. At 2.5 and 3.5 years of age, during intercurrent illness, the index presented with lethargy, hyperammonemia, and hyperlactatemia. Hyperammonemia resolved with a single dose of carglumic acid. She has remained clinically stable with L-carnitine, vitamin C, coenzyme Q10, and ''sick-day management'' with high-caloric and lipid-rich formula during illnesses. At the age of 4.5 years, she exhibited mild axial hypotonia and septal thickening on cardiac ultrasound. Developmental and behavioral assessment at age 4.5 confirmed average functioning in all domains except for below-average motor coordination (Beery Buktenica Developmental Test of Visual-Motor Integration). The male sibling at age 2.3 years had difficulty engaging in an assessment as a result of heightened activity and self-directed behavior; scores on Bayley Scales of Infant and Toddler Development (Third Edition) were below average. Biochemical profiles and somatic and psychomotor development are unremarkable in the unaffected younger sibling, now 1.5 years of age.
WES was performed for the two affected siblings and their unaffected parents via the Agilent SureSelect kit and Illumina HiSeq 2000 (Perkin-Elmer). Rare variants were assessed for their potential to disrupt protein function and screened under a series of genetic models-primarily the Mendelian recessive mode of inheritance given the rarity of the phenotype and the pattern of inheritance of most IEMs.
Approximately 99% of the observed variations were classified as common (Table S1 available variants in the affected siblings. The final set of rare variants (mean average frequency < 1%) was assessed for the potential to disrupt protein function via the Sift and PolyPhen2 software systems. Of these, only one variant (c.697T>C; RefSeq accession number NM_001739.1) in CA5A on chromosome 16 was considered a functional candidate; this variant was not reported in dbSNP (version 137), NHLBI ESP, or our in-house genome database (comprising 100 exomes and 10 whole genomes; anno December 2013). Integrative Genomics Viewer 2.0.34 was used to visualize the read alignment and assess variant quality prior to Sanger validation. Given the existence of a related pseudogene, 3 the CA5A variant was confirmed by targeted Sanger sequencing via carefully designed primers to avoid amplification of the pseudogene sequences; this was achieved by review of paired-end sequence data and selection via a BLAST search of appropriate regions with least similarity, especially close to the 3 0 end. Affected siblings are confirmed homozygous, whereas unaffected parents and the unaffected youngest female are heterozygous carriers ( Figures 1A and 1B) . This variant corresponds to a Ser to Pro substitution at position 233 that is predicted to disrupt structure around the conserved Thr235 residue that forms part of the substrate-binding region of the enzyme (Figure 2) . Indeed, the p.Ser233 residue is highly conserved evolutionarily across species and in all 12 active human carbonic anhydrase isoforms. Studies of human CA-II have demonstrated that mutations in this hydrophobic patch in the active site destabilize the structure around the substrate-binding region and dramatically reduce the activity of the mutant CA-II. 4 Tissues with CA-VA (liver, kidney, skeletal muscle) were not available for the affected siblings. Therefore, the effect of the p.Ser233Pro substitution on CA-VA was characterized in cultured mammalian cells (COS-7). A marked reduction was observed in the steady-state levels of CA-VA p.Ser233Pro compared with wild-type protein despite similar transfection efficiencies ( Figure 1C ). As summarized in Table 2 , CA-VA p.Ser233Pro-specific activity in total cell lysates is reduced to 20% of wild-type protein activity, whereas activities of the cotransfected marker enzyme b-glucuronidase were comparable. There was a negligible change in the activity of mutant enzyme in the presence of added zinc (22% of WT), suggesting that both WT and mutant enzymes in COS-7 cells are saturated with zinc (data not shown). Thermal stability of mutant recombinant human CA-VA was compared with the WT CA-VA and recombinant human Carbonic Anhydrase II as an additional control ( Figure 1D ). After a 30 min preincubation, the mutant enzyme had lost 80% of its activity at 30 C and almost all its activity at 40 C. By contrast, both WT CA-VA and human CA-II were much more stable at 30 C and 40 C, retaining approximately 100% and 70% residual activity, respectively. In a separate experiment (Table 3) , preincubation of the mutant enzyme at 37 C (normal human body temperature) for 30 min retained only 5% of mutant enzyme activity, whereas wild-type protein activity was 80% relative to activity after a 4 C preincubation. In family 2, a male child (II-1 in Figure 3A ) was born spontaneously at gestational age 36 þ2 weeks to noncon- investigations are shown in Table 1 ; molecular analysis of CPS1 and NAGS did not reveal disease-causing mutations. Carglumic acid and biotin were initiated, along with protein-free formula and intravenous lipids; 12 hr later, the metabolic acidosis and hyperammonemia resolved. He resumed breastfeeding with normal weight gain, ammonia levels, and urine metabolites. Carglumic acid was stopped at 4 months of age, and the infant exhibited normal psychomotor development at age 6 months with the use of sick-day formula during illness. Sanger sequencing of all seven exons of CA5A in the index identified a synonymous c.555G>A transition (RefSeq NM_001739.1) at the final base of exon 4 ( Figure 3B ). Given that guanine is the most common nucleotide found at this end of an exon in vertebrate genes, RT-PCR was undertaken to demonstrate an effect on mRNA splicing. 7 RNA was purified from white blood cells of the index and a control subject. RT-PCR via primers designed to amplify exons 2-7 of CA5A generated distinctly different product sizes (approximately 550 bp and 650 bp, respectively; Figure 3B ). Sanger sequencing of the~550 bp band revealed an in-frame deletion of exon 4 from the index RNA ( Figure 3C ). We cannot exclude the presence of other transcripts in vivo, which were missed because of the limited sensitivity of the assay combined with low CA5A expression in white blood cells. Alternatively, this single transcript may be explained by preferential formation during the transcription/splicing processes. Homology with carbonic anhydrase isoforms identifies three critical residues in the deleted CA-VA transcript (residues 154-185): His155, which binds to a catalytically essential zinc molecule, and Tyr164 and Tyr167, which form part of the active site of the CA-VA enzyme. 8 Thus, this deletion is predicted to significantly impair CA-VA enzyme activity, if not lead to protein misfolding and degradation. In family 3, a male child (II-5 in Figure 4A ) was born at term by Caesarian section (because of placenta previa) as the youngest of five children to first-cousin consanguineous Pakistani parents. At 13 months of age, after unremarkable development, he presented with a 1-day history of visual unresponsiveness. At admission, he was encephalopathic with hyperammonemia (258 mmol/l) and hyperlactatemia (4.9 mmol/l), with a compensated metabolic acidosis (pH 7.43, pCO 2 . He continues to have infrequent episodes of vomiting and ketoacidosis without hyperammonemia or lactic acidosis; the frequency of these episodes has not increased since the withdrawal of sodium benzoate and arginine therapy at the age of 7 years. Sanger sequencing of the CA5A exons for the index revealed a deletion of 4 kb encompassing exon 6 ( Figure 4B ). Relative copy number was assessed in the family via qPCR of exon 6 sequence, confirming the homozygous deletion in the two siblings and heterozygosity in the parents ( Figure S1 ). Absence of CA-VA protein was confirmed by immunoblot in existing liver biopsy tissue ( Figure 4C ). Limited information is available on the neonatal and early childhood course in his four older siblings; parents reported no major health problems and normal learning ability. The oldest brother (II-2 in Figure 4) is homozygous for the CA5A deletion but declined further evaluation at age 17. Neonatal or childhood insults and a possible mild presentation cannot be excluded because of limited history. A benign clinical course after early childhood is consistent with the index cases of each of the three families after initial metabolic decompensations. The condition may exhibit intrafamilial variability of the phenotype, as reported for other inborn errors of metabolism. 9, 10 CA-VA deficiency is a human inborn error of metabolism presenting with hyperammonemic encephalopathy in early life. Initial evidence of causality for the identified CA5A alterations is provided by their similar biochemical phenotypes during metabolic crises. Findings are consistent with dysfunction of all four enzymes to which CA-VA provides bicarbonate as substrate in mitochondria and thus the two intramitochondrial carbonic anhydrases (CA-VA and CA-VB) are pivotal in providing HCO 3 À for multiple mitochondrial enzymes that catalyze the formation of essential metabolites of intermediary metabolism in the urea and Krebs cycles ( Figure 5 ).
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These include CPS1, which catalyzes the synthesis of carbamoylphosphate from ammonia and bicarbonate, a rate-limiting step in the conversion of waste nitrogen into urea, and pyruvate carboxylase (PC), which stands at the interface between glycolysis and the Krebs cycle, facilitating the production of oxaloacetate from pyruvate, the former being a major anaplerotic substrate essential for the maintenance of the Krebs cycle. 13 Primary PC deficiency is biochemically characterized by lactic acidosis, hyperammonemia, and hypoglycemia, as was observed in our CA-VA-deficient individuals with presumed secondary PC deficiency leading to hypoglycemia through impaired gluconeogenesis.
14 CA-VA deficiency provides the unique opportunity to study the opposite consequences of CPS1 deficiency (hyperammonemia, elevated glutamine, and decreased citrulline and other amino acids distal to the block) and PC deficiency (hyperammonemia, normal to decreased glutamine, increased citrulline and lysine). Given that glutamine was elevated in three of the four affected individuals and that the citrulline was low to normal in all, it appears that an impaired urea cycle, rather than deficient glutamate, was the major cause of hyperammonemia. Combined with the normal lysine levels and relatively mild elevations of 2-a-ketoglutaric acid and other Krebs cycle intermediates, the biochemical profiles in our CA-VA deficiency individuals support a predominant effect of (secondary) CPS1 versus PC deficiency.
The observed moderate increase of urinary 3-OH propionic acid, propionyl glycine, and methylcitrate along with traces of 3-methylcrotonylglycine are consistent with the expected reduced activities of PCC and 3MCC in CA-VA deficiency. Although biotinidase and holocarboxylase synthetase (HCS [MIM 253270]) deficiencies share the metabolite profiles of secondary PC, PCC, and 3MCC deficiencies, there are three major differences relative to primary CA-VA deficiency: (1) the significantly higher level of PCC and 3MCC metabolites in (even wellcontrolled) individuals with the two former disorders compared to those with CA-VA deficiency during metabolic decompensation; (2) the presence of CPS1 deficiency as (likely) major cause of hyperammonemia in CA-VA Table 3 . Although not approved for this indication, carglumic acid may be of benefit as synthetic treatment of partial CPS1 deficiency through its known ability to enhance the activity of this enzyme. 2 This could increase production of carbamoyl phosphate even at HCO 3 À levels below the Km for the enzyme. Although the hyperammonemia resulted from a reduction of substrate to CPS1, rather than a primary CPS1 deficiency, three individuals (families 1 and 2) showed a good response to carglumic acid (normalization of ammonia and for the female of family 1, a mild increase of citrulline), consistent with the suggestion that enhanced CPS1 activity can partially compensate for reduced HCO 3 À resulting from CA-VA deficiency. This hypothesis should be tested in the Car5A-null mouse model (Car5Adl1Sws), 18 especially given the high cost of this medication and uncontrolled circumstances in which these children were managed with multiple therapeutic modalities. Newborn screening profiles (Tandem MS/MS), specifically C3 and C5OH levels, were unremarkable in all four cases, probably because of the relatively mild biochemical profile for the carboxylase-related metabolites along with the low sensitivity of acylcarnitine analyses compared to urine organic acids. Furthermore, outside of acute events, biochemical parameters remained normal in all affected , 26 and carbonic anhydrase II (CA 2) 27 via specific antibodies.
children except for mildly elevated blood lactate and/or ketonuria. We propose several explanations for the relatively benign clinical course in these individuals and lack of apparent phenotype in the oldest male sibling in family 3. First, overlapping function of CA-VB may help prevent deleterious sequelae of reduced CA-VA activity. 19 In the mouse, Car5A is mainly localized in liver and its deficiency results in profound hyperammonemia. Car5B, though almost undetectable in liver, is predominant in mitochondria of many other tissues. Nonetheless, Car5B deficiency alone has no obvious phenotype. However, when superimposed on Car5A deficiency in the doubly deficient mouse (Car5Adl1Sws/ Car5Bdl1Sws), Car5B deficiency aggravated the hyperammonemia and hypoglycemia and shortened survival. 18 Thus, Car5B does contribute to handling the metabolic load, though its action is evident only in the absence of Car5A. Second, although carbonic anhydrases accelerate the conversion of CO 2 to HCO 3 À by 1,000-fold or greater, some bicarbonate is produced via the nonenzymatic reaction, even in the absence of carbonic anhydrases. 20 Sufficiency for the product of this limited nonenzymatic source of bicarbonate may differ for the four different bicarbonate-requiring enzymes depending on their individual Kms. Thus, CA-VA deficiency should be considered among urea cycle defects, organic acidurias, and PC deficiency in the differential diagnosis for hyperammonemia and hyperlactatemia in the neonate and young child. Whereas many of the biochemical markers are nonspecific, some metabolites such as propionylglycine and 3-methylcrotonylglycine are more specific for deficiencies of PCC and 3MCC deficiencies that occur secondary to CA-VA deficiency. However, the increase in these metabolites is subtle compared with individuals who have a primary defect of these enzymes. Furthermore, these abnormalities may be present only during symptomatic episodes. Therefore, diagnostic molecular analysis of CA5A should be considered in persons with suggestive biochemical findings.
CA-VA deficiency expands the list of treatable inborn errors of metabolism potentially causing intellectual disability. 21 Effective therapy in the affected individuals comprised (1) preventive sick-day management during intercurrent illnesses, including a high-caloric, lipid-rich formula restricted in protein but normal in carbohydrates; and possibly (2) carglumic acid to enhance the activity of the first step in the urea cycle as a treatment for the hyperammonemia.
Other experimental therapies deserving exploration include oral zinc supplementation (a CA-VA cofactor that may increase residual activity in persons with mutations outside the zinc-binding site) and interventions to enhance or replace anaplerosis to alleviate metabolic symptoms of PC dysfunction, such as the administration of aspartate and citrate (but not triheptanoin, given the secondary PCC deficiency 22 ), as demonstrated by improved growth and survival in CA-VA-null mice receiving citrate water.
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Supplemental Data include one figure and one table and can be found with this article online at http://www.cell.com/AJHG/.
Accession Numbers
The Leiden Open Variation Databank (http://databases.lovd.nl/ shared/genes/CA5A) accession number for the c.697T>C mutation reported in this paper is CA5A_000001; for the c.555G>A mutation, CA5A_000002; and for the 4,078 bp exon 6 deletion is CA5A_000003. 
